S.3565 - Opioid Advocacy Transparency Act of 2018115th Congress (2017-2018)
|Sponsor:||Sen. McCaskill, Claire [D-MO] (Introduced 10/10/2018)|
|Committees:||Senate - Finance|
|Latest Action:||Senate - 10/10/2018 Read twice and referred to the Committee on Finance. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Summary: S.3565 — 115th Congress (2017-2018)All Information (Except Text)
Introduced in Senate (10/10/2018)
Opioid Advocacy Transparency Act of 2018
This bill expands reporting requirements related to the ownership and investment interests of certain patient-advocacy organizations.
Under current law, a manufacturer of drugs, devices, or medical supplies that are covered under Medicaid or Medicare must regularly report on any payment or transfer of value by the manufacturer to a "covered recipient," defined as either a physician who is not an employee of the manufacturer or a teaching hospital. The bill expands the definition of "covered recipient," for purposes of this requirement, to also include patient-advocacy organizations that advocate on issues related to opioids. Furthermore, with respect to transfers of value to such organizations, the bill subjects not only manufacturers but also pharmaceutical trade associations to the reporting requirement.